more_reports

Francois Brisebois

Oppenheimer & Co.

Francois Brisbois is managing director and senior analyst at Oppenheimer & Co. Inc. covering biotechnology. Prior to joining Oppenheimer, he was a senior research analyst at Craig-Hallum Capital covering biotechnology and biopharmaceuticals. He previously worked at Laidlaw Capital Markets as a senior analyst covering biotechnology and specialty pharmaceuticals and started his Wall Street career at healthcare specialty firm Summer Street Research Partners. Brisebois holds a bachelor's degree in molecular biology from Colgate University and a Master of Science in pharmaceutical sciences from University of Montreal.

Recent Articles about Sensei Biotherapeutics Inc.

Biotech Advances Breakthrough Cancer Treatment Results 01/10/2025

Sensei Biotherapeutics Inc. (SNSE:NASDAQ) is "well-positioned" to provide a clinical update on its drug targeting advanced solid tumors, Solnerstotug, in 2Q 2025, Oppenehimer & Co. Analyst Francois Brisebois writes in an updated research note.